Akebia Therapeutics, Inc.
About Akebia Therapeutics, Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $236.2M
- Net income
- -$5.3M
- Total assets
- $376.6M
- Market cap
- $250.9M
- Gross margin
- 83.3%
- Operating margin
- 9.9%
- Net margin
- -2.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $236.2M
- Cost of revenue
- $39.5M
- Gross profit
- $196.7M
- Operating expenses
- $173.2M
- Operating income
- $23.5M
- Income tax
- $1.6M
- Net income
- -$5.3M
- EPS (basic)
- $-0.02
- EPS (diluted)
- $-0.02
Balance sheet
- Total assets
- $376.6M
- Current assets
- $253.0M
- Total liabilities
- $344.0M
- Current liabilities
- $162.9M
- Shareholders’ equity
- $32.6M
Cash flow
- Operating cash flow
- $68.0M
- Investing cash flow
- -$7.9M
- Financing cash flow
- $72.9M
- Net cash flow
- $133.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $250.9M
- EPS (diluted)
- $-0.02
- Shares outstanding
- 266.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 20, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $5.3M in FY2025.
- Revenue grew 11% from FY2021 to FY2025.
- Gross margin of 83.3%, net margin -2.3%.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Akebia Therapeutics, Inc..
Write a review
News about Akebia Therapeutics, Inc.
News & sentiment via Polygon.io
